American Vanguard (AVD) Tops Q4 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/30/2026
- S&P 500 dips, Nasdaq higher after data shows moderate inflation rise
- Equity positioning stays overweight, but summer extremes have eased: Barclays
- Oil prices rise by about $1/bbl on stalled US-Iran talks and tight fuel markets
- Micron reports Q4 today: Why Lynx Equity sees massive upside
- Moderna: Citi says oncology optimism is priced in, cuts rating to sell
- Salesforce agrees to acquire AI research platform Listen Labs
- Workday cuts 2.5% of workforce, revises GAAP margin outlook
- Zimbabwe helicopter crash kills six, government spokesperson says
- Apple's iOS 27 is blocking Trade Desk ads on Safari, analyst says
- S&P 500 dips, Nasdaq higher after data shows moderate inflation rise
American Vanguard Reports Fourth Quarter & Full Year 2015 Results
March 1, 2016 4:10 PM ESTNEWPORT BEACH, Calif.--(BUSINESS WIRE)-- American Vanguard Corporation (NYSE: AVD) today announced financial results for the fourth quarter and full year ended December 31, 2015.
Fiscal 2015 Fourth Quarter Financial Highlights versus Fiscal 2014 Fourth Quarter:
Net sales were $84.0 million in Q4 2015 compared to $77.6 million in Q4 2014. Net income was $3.0 million in Q4 2015 compared to $1.8 million in Q4 2014. Earnings per diluted share were $0.10 in Q4 2015 versus $0.06 in Q4 2014.Fiscal 2015 Financial Highlights versus Fiscal 2014:
Net sales were $289.4 million in FY 2015 compared to... MoreAmerican Vanguard Announces Investment in Biological Products & Technologies
March 1, 2016 4:05 PM ESTNEWPORT BEACH, Calif.--(BUSINESS WIRE)-- American Vanguard Corporation (NYSE: AVD) and Bi-PA, today announced that American Vanguard Corporation wholly-owned subsidiary, AMVAC-Netherlands BV, has become an investor in Biological Products for Agriculture (Bi-PA). Bi-PA functions as a product development engine bridging basic research/discovery and end-market commercialization. It accomplishes this commercial development by focusing on optimizing formulations and securing regulatory approval. This investment affords American Vanguard a 15% share of Bi-PAs total enterprise valuation; distribution rights in the Americas for Bi-PAs Vintec® Trichoderma biological fungus control agent and subsequent products; and... More
